

10th World Congress on

HEALTHCARE & TECHNOLOGIES

July 17-18, 2017 | Lisbon, Portugal



Domenico Mastrangelo

University of Siena, Italy

RATIONALE FOR THE USE OF MEGADOSES OF VITAMIN C IN THE TREATMENT OF CANCER

The selective anticancer properties of Vitamin C are known since at least four decades. However, only recently *in vitro* studies have shown that Vitamin C, in high enough concentrations, can efficiently and selectively kill a number of different human tumor cell lines, and these data have been confirmed in experimental animal tumor models.

The first human clinical trials, revealed that high doses of Vitamin C administered by intravenous injection, are not only very well tolerated, but substantially improve the quality of life of patients with clinically advanced cancer. However the clinical evidence of the effectiveness of Vitamin C in fighting off cancer, is still controversial.

The present paper outlines the importance of Vitamin C for a number of physiologic functions, within the human body and shows that there is a solid rationale for its use in the routine treatment of cancer, either alone or in combination with conventional treatment.

Biography

Domenico Mastrangelo has completed his degree in Medicine and Surgery on October 26th, 1979, at the age of 24. He then specialized in hematology in 1983, Oncology in 1987, Clinical Pharmacology in 1990, Ophthalmology in 2010. His experience is in the fields of hematological/oncological epidemiology and laboratory, cell biology molecular biology. He published more than 100 papers in reputed scientific journals, including chapters in highly reputed scientific books, in the fields of ocular oncology clinical oncology, cancer cell biology, and hematology. Presently he is a Senior Scientist at the Department of Medical, Surgical, and Neurological Sciences of the University of Siena, Italy.

mastrangelo@unisi.it